100
Participants
Start Date
October 9, 2015
Primary Completion Date
April 13, 2017
Study Completion Date
July 7, 2025
CC-486
CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
Pembrolizumab
Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
Placebo
Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
Local Institution - 006, New York
NYU Langone Medical Center, New York
Local Institution - 302, Berlin
Local Institution - 200, Marseille
Local Institution - 903, Athens
Georgetown University Medical Center, Washington D.C.
Local Institution - 602, Milan
Local Institution - 606, Milan
Local Institution - 703, Madrid
Local Institution - 701, Madrid
Local Institution - 704, Madrid
Local Institution - 706, Madrid
Local Institution - 600, Novara
University Cancer and Blood Center, LLC, Athens
Local Institution - 203, Toulouse
Local Institution - 601, Aviano
Local Institution - 700, Valencia
Local Institution - 705, Barakaldo
Local Institution - 304, Cologne
Washington Univ School of Medicine, St Louis
Research Medical Center, Kansas City
Local Institution - 204, Lyon
Local Institution - 300, Esslingen am Neckar
Local Institution - 301, Löwenstein
Local Institution - 603, Napoli, Campania
Palo Verde Hematology Oncology, Glendale
UCLA Hematology Oncology, Los Angeles
Local Institution - 201, Villejuif
Local Institution - 604, Catania
North Shore Hematology Oncology Associates, East Setauket
Vanderbilt Univ Medical Center, Nashville
Local Institution - 605, Roma
Local Institution - 702, Barcelona
Lead Sponsor
Celgene
INDUSTRY